|
(R*,S*)-(±)-2-Methyl-4aa-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aa-octahydroquinolino[2,3,3-g]isoquinoline dihydrobromide Suppliers list
|
| Company Name: |
HANGZHOU CLAP TECHNOLOGY CO.,LTD |
| Tel: |
86-571-88216897,88216896 13588875226 |
| Email: |
sales@hzclap.com |
| Products Intro: |
Product Name:(R*,S*)-(±)-2-Methyl-4aa-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aa-octahydroquinolino[2,3,3-g]isoquinoline dihydrobromide
CAS:1217628-73-3
Purity:24999% Package:10kg 25kg 200 kilograms per barrel Remarks:good
|
|
|
|
|
(R*,S*)-(±)-2-Methyl-4aa-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aa-octahydroquinolino[2,3,3-g]isoquinoline dihydrobromide manufacturers
- TAN67
-
- $1260.00
-
2026-07-15
- CAS:1217628-73-3
- Purity:
- Supply Ability: 10g
|
| | (R*,S*)-(±)-2-Methyl-4aa-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aa-octahydroquinolino[2,3,3-g]isoquinoline dihydrobromide Basic information |
| Product Name: | (R*,S*)-(±)-2-Methyl-4aa-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aa-octahydroquinolino[2,3,3-g]isoquinoline dihydrobromide | | Synonyms: | SB 205607 HCI | | CAS: | 1217628-73-3 | | MF: | C23H25BrN2O | | MW: | 425.37 | | EINECS: | | | Product Categories: | | | Mol File: | 1217628-73-3.mol | ![(R*,S*)-(±)-2-Methyl-4aa-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aa-octahydroquinolino[2,3,3-g]isoquinoline dihydrobromide Structure](CAS/20211123/GIF/1217628-73-3.gif) |
| | (R*,S*)-(±)-2-Methyl-4aa-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aa-octahydroquinolino[2,3,3-g]isoquinoline dihydrobromide Chemical Properties |
| solubility | Soluble to 100 mM in water and to 100 mM in DMSO | | form | Powder | | color | White to off-white |
| | (R*,S*)-(±)-2-Methyl-4aa-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aa-octahydroquinolino[2,3,3-g]isoquinoline dihydrobromide Usage And Synthesis |
| Uses | SB 205607 Dihydrobromide is a selective δ-opioid receptor-1 agonist. | | in vivo | TAN-67 (SB-205607; 1.5-4.5 mg/kg; i.v.; once) dihydrobromide reduces infarct volume in I/R-caused brain injury[2].
TAN-67 (3 mg/kg; i.v.; once) dihydrobromide improves survival and neurobehavioral performance after I/R[2].
TAN-67 (3 mg/kg; i.v.; once; adult C57BL/6J male mice) dihydrobromide increases both total APP and mature APP (APPm) levels and APP processing at an early time point (6 h)[2].
| Animal Model: | Adult C57BL/6J male mice with I/R-caused brain injury[2] | | Dosage: | 1.5, 3.0, and 4.5 mg/kg | | Administration: | Intravenous injection; once | | Result: | Reduced infarct volume in a dose-dependent manner. |
| Animal Model: | Adult C57BL/6J male mice with I/R-caused brain injury[2] | | Dosage: | 3.0 mg/kg | | Administration: | Intravenous injection; once | | Result: | Had rapidly functional recovery than the vehicle-treated mice.
Reduced neuronal cell death.
|
| Animal Model: | Adult C57BL/6J male mice with transient middle cerebra artery occlusion (MCAO) ischemic stroke model[2] | | Dosage: | 3.0 mg/kg | | Administration: | Intravenous injection; once | | Result: | Increased both total APP and mature APP (APPm) levels.
Reduced β-secretase activity.
|
| | IC 50 | δ Opioid Receptor/DOR: 0.647 nM (Ki) | | storage | Store at RT |
| | (R*,S*)-(±)-2-Methyl-4aa-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aa-octahydroquinolino[2,3,3-g]isoquinoline dihydrobromide Preparation Products And Raw materials |
|